Vaxcell-Bio Therapeutics (323990.KS)
Company Info
Highlights
₩6,970.00 - ₩18,550.00
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Vaxcell-Bio Therapeutics (323990.KS) returned -7.96% year-to-date (YTD) and -44.25% over the past 12 months.
323990.KS
-7.96%
-0.21%
-27.27%
-44.25%
-35.14%
N/A
N/A
^GSPC (Benchmark)
0.51%
3.96%
-2.00%
12.02%
12.68%
14.19%
10.85%
Monthly Returns
The table below presents the monthly returns of 323990.KS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -1.15% | -9.02% | -13.43% | 24.01% | -4.67% | -7.96% | |||||||
| 2024 | -15.46% | 1.16% | 7.81% | -20.82% | 5.06% | -13.47% | 9.19% | -6.70% | -4.41% | -11.10% | 2.33% | -20.98% | -53.54% |
| 2023 | 2.78% | -2.56% | 13.89% | 2.70% | -0.88% | -11.10% | 3.40% | 15.23% | -27.32% | -18.12% | -1.29% | 20.76% | -12.75% |
| 2022 | -21.08% | -0.15% | 33.04% | -1.10% | 3.78% | -17.34% | 62.95% | 13.20% | -43.40% | -10.05% | 6.76% | -11.76% | -21.31% |
| 2021 | -21.16% | -0.68% | -14.50% | -18.84% | 8.91% | -8.59% | -10.06% | -3.19% | -12.94% | -5.98% | -18.45% | -17.49% | -74.06% |
| 2020 | 27.23% | 70.48% | 102.16% | 258.24% | 1,470.89% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of 323990.KS is 19, meaning it’s performing worse than 81% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Vaxcell-Bio Therapeutics (323990.KS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Vaxcell-Bio Therapeutics. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Vaxcell-Bio Therapeutics was 96.36%, occurring on Apr 9, 2025. The portfolio has not yet recovered.
The current Vaxcell-Bio Therapeutics drawdown is 95.27%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -96.36% | Jan 8, 2021 | 1044 | Apr 9, 2025 | — | — | — |
| -34.1% | Nov 10, 2020 | 4 | Nov 13, 2020 | 2 | Nov 17, 2020 | 6 |
| -23.75% | Sep 29, 2020 | 11 | Oct 19, 2020 | 5 | Oct 26, 2020 | 16 |
| -12.3% | Nov 23, 2020 | 6 | Nov 30, 2020 | 1 | Dec 1, 2020 | 7 |
| -9.96% | Dec 28, 2020 | 1 | Dec 28, 2020 | 1 | Dec 29, 2020 | 2 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Vaxcell-Bio Therapeutics over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Vaxcell-Bio Therapeutics, comparing actual results with analytics estimates.
Valuation
The Valuation section provides an overview of how Vaxcell-Bio Therapeutics is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for 323990.KS relative to other companies in the Biotechnology industry. Currently, 323990.KS has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for 323990.KS in comparison with other companies in the Biotechnology industry. Currently, 323990.KS has a P/B value of 0.0. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |